

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT

BIVALENT mRNA VACCINE AGAINST COVID-19 VARIANTS DELTA AND OMICRON BA.5 OBTAINED CLINICAL TRIAL APPROVALS FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that recently, the bivalent mRNA vaccine against COVID-19 variants Delta and Omicron BA.5 developed by the Group obtained clinical trial approvals from the National Medical Products Administration of China.

Previously, this vaccine was approved to commence Phase III clinical trials in Pakistan. Such clinical trials are currently in their closing stages. Upon completion of the relevant clinical trials, a new drug application will be filed for the vaccine to be launched in Pakistan.

The Group will soon commence Phase I/II clinical trials of this vaccine in China. Upon completion of the relevant clinical trials, the Group will consolidate the Phase III clinical data of the vaccine in Pakistan and file a new drug application for the vaccine to be launched in China.

Meanwhile, investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, June 29, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.